6 Cheapest Semaglutide Providers (2026)

How we calculate the real all-in price (and why intro rates mislead)

Every provider in this comparison posts a headline number. Almost none of them show the full monthly cost on the landing page. The actual number that matters is the all-in maintenance rate — medication fee, plus any membership or platform fee, plus shipping, at the dose you will actually stay on long-term.

Intro rates (first-month discounts, promotional pricing, annual-plan averages) are real savings, but they disappear. The table above reflects the ongoing all-in cost after any promotional period, at a typical starting dose. Where pricing steps up with dose titration, we note it.

• Medication fee: what you pay for the drug itself, per month.
• Membership / platform fee: a separate recurring charge for provider access, care coordination, and messaging — common at Alloy, Mochi, Hers, and Ro.
• Shipping: most compounded programs include it; verify before enrolling.
• Lab fees: some programs bill labs separately. Ask specifically.
• Dose-escalation costs: compounded programs at some providers (Henry Meds) add ~$100/mo per dose tier above the entry dose.

Alloy Health — best for women in perimenopause who want the lowest all-in rate

Alloy's compounded semaglutide program is the cheapest all-in option we can verify for menopause-focused care: $70 a month for the medication, plus $99 a month for the Weight Care membership. The $99 membership is not just an access fee — it covers unlimited messaging with a physician who specializes in menopause, wellness check-ins, dose adjustments, and side-effect management. For women in perimenopause dealing with both hormonal change and weight gain simultaneously, the menopause-specific clinical model matters.

The trade-off is geography. Alloy does not currently operate in AL, AR, CA, NV, LA, MS, or DC. If you are in one of those states, Alloy is not available to you — move to Mochi or Fridays.

• All-in cost: ~$169/mo ($70 medication + $99 membership).
• Annual cost: roughly $2,028/yr at that rate.
• Not available in: AL, AR, CA, NV, LA, MS, DC.
• Compounded: yes — 503A individual-patient pathway.
• Menopause specialization: the standout differentiator.

Mochi Health — best for dose-flat pricing in all 50 states

Mochi Health charges a flat $99 a month for compounded semaglutide at any dose — meaning your medication cost does not increase as you titrate up through the dosing schedule. Combined with the $79 monthly membership, the all-in ongoing cost is $178 a month. The first month runs $138 because the membership drops to $39 as a new-patient promotion.

For women who expect to titrate to a higher dose and stay there, the flat medication fee is genuinely valuable. A provider whose compounded semaglutide costs $149 a month at the starter dose but $249 at the maintenance dose can end up more expensive than Mochi over a full year. Mochi is also one of the few programs with explicit 50-state availability — worth confirming directly if you are in a state with unusual compounding restrictions.

• All-in cost: $178/mo ($99 flat medication + $79 membership).
• Annual cost: roughly $2,136/yr.
• Dose-flat medication: $99 whether you are at the starting dose or the maintenance dose.
• First month: $138 ($39 membership promo).
• States: available in all 50 states (terms vary by state).
• Compounded: yes — 503A.

Fridays — best annual value with coaching and care bundled

Fridays takes a different approach to pricing: one monthly rate that covers everything — medication, unlimited provider visits, dietitian coaching, group coaching sessions, access to the SESH fitness app, and shipping. There is no separate membership fee. Month-to-month, that all-inclusive rate is $249. Commit to a year and it drops to $150 a month. The three-month plan sits at $199.

If you are someone who will actually use the coaching and nutrition support, Fridays' bundled model can represent substantial value at the annual rate. A competing program charging $150 for medication alone still puts you at $228+ once you add a membership. The question is whether the behavioral support is something you want, or whether you would rather pay for the medication separately and skip the coaching.

• Annual plan: $150/mo all-in — medication, coaching, unlimited visits, shipping.
• 3-month plan: $199/mo.
• Month-to-month: $249/mo.
• Annual cost (annual plan): roughly $1,800/yr — the lowest yearly number in this comparison.
• No separate membership fee: everything is in the one price.
• Compounded: yes — 503A.

Henry Meds — best for no-commitment month-to-month with everything bundled

Henry Meds charges no membership fee. The monthly price covers the medication, provider visits, supplies, and shipping. Injectable compounded semaglutide runs $297 a month on a month-to-month basis, dropping to $247 on a six-month plan and $197 on a twelve-month prepay. The $297 MTM rate is the most transparent pricing structure among the larger compounded programs — no hidden membership to stack on top.

Henry Meds also offers oral and sublingual semaglutide formats at $249 a month (lower starting dose options). One cost watch: dose escalation above the baseline adds approximately $100 a month per tier at higher doses. Confirm the full dose-cost ladder before you start, since most patients do not stay at the starter dose for the long term.

• Injectable, month-to-month: $297/mo all-in.
• Injectable, 12-month prepay: $197/mo.
• Oral/sublingual options: from $249/mo.
• Annual cost (12-month injectable): roughly $2,364/yr.
• No membership fee: bundled pricing.
• Higher-dose surcharge: ~$100/mo per tier above base — ask for the full ladder.
• Compounded: yes — 503A.

Hers — best if you want brand-name Wegovy with women-focused support

Hers no longer advertises compounded semaglutide. In September 2025, the FDA issued a warning letter to Hers citing misleading claims around compounded semaglutide. By March 2026, Hims & Hers reached an agreement with Novo Nordisk and announced a strategic shift: the platform now offers FDA-approved Wegovy (pill and pen) rather than compounded alternatives.

The all-in cost at Hers is higher than the compounded programs above. The Weight Loss Membership is $149 a month after the first month ($39 intro). Wegovy pill pricing starts at $149 a month for the starting dose, stepping up with higher doses. At the entry level, you are looking at roughly $298 a month combined — and that climbs with dose. If your insurance covers Wegovy, or if you qualify for the NovoCare savings card, the brand-name option becomes far more competitive.

• Membership: $149/mo (ongoing, $39 first month).
• Wegovy pill: from $149/mo at the starting dose.
• All-in entry: ~$298/mo.
• Compounded semaglutide: no longer actively offered.
• FDA-approved brand: yes — Wegovy pill and pen.
• Insurance: worth checking; Wegovy coverage can reduce medication cost dramatically.

Ro — best for brand Wegovy access with an established telehealth platform

Ro is one of the telehealth platforms that partnered directly with Novo Nordisk to offer brand-name Wegovy at reduced self-pay rates. The Ro Body membership runs $149 a month on a monthly plan ($74 a month if you prepay annually). The Wegovy pill starts at $149 a month for the lowest doses, with a limited-time introductory offer of $199 for the first two months on the Wegovy pen (valid through June 30, 2026 per Ro's current promotion). Higher doses run $199–$299 a month.

The math on Ro depends heavily on which membership tier you choose. On the annual membership ($74/mo) plus the Wegovy pill at $149/mo, the all-in rate is $223 a month at the starting dose — approaching the higher end of the compounded programs. On a monthly membership plan with a higher dose, costs can reach $448 a month. Ro makes most sense for patients who want FDA-approved brand Wegovy with a clinically managed program and are weighing cost against regulatory simplicity.

• Membership: $149/mo MTM; $74/mo annual prepay.
• Wegovy pill: $149–$299/mo depending on dose.
• All-in range: $223/mo (annual membership + starting dose) to $448/mo (MTM membership + high dose).
• Compounded semaglutide: not the primary offering as of 2026.
• FDA-approved brand: yes — Wegovy pill and pen.
• June 2026 promo: Wegovy pen at $199 first two months (verify still active at time of enrollment).

Is compounded semaglutide still legal in 2026?

The short answer is yes — with significantly narrower guardrails than two years ago. In February 2025, the FDA declared the semaglutide shortage resolved, ending the broad exemption that had allowed 503B outsourcing facilities to compound semaglutide at scale for the mass market. Large-scale compounding for office stock is no longer permitted.

What remains is the 503A individual-patient pathway. A licensed 503A compounding pharmacy can legally fill a prescription for a specific named patient when a licensed physician documents a clinical need for that individual. This is the pathway all four compounded programs in this comparison (Alloy, Mochi, Fridays, Henry Meds) use today. The prescription comes from your telehealth provider; the pharmacy mixes and ships to you specifically.

As of April 30, 2026, the FDA also proposed excluding semaglutide from the 503B Bulks List — which would shut the door on any future large-scale 503B compounding. The public comment period closed June 29, 2026; a final rule has not been issued as of this writing. The 503A individual-patient pathway is not affected by this proposal.

• 503A (individual-patient) compounding: currently legal — this is what most telehealth programs use.
• 503B (outsourcing facility, bulk): large-scale compounding no longer permitted for semaglutide; FDA proposed full exclusion from 503B Bulks List (April 2026).
• What this means for you: your telehealth program should be using a state-licensed 503A pharmacy filling your individual prescription. Ask your provider directly which pharmacy they use and whether it is 503A or 503B.
• Hers and Hims: both received FDA warning letters in September 2025 for misleading compounded semaglutide claims; both have since shifted to brand-name Wegovy offerings.

Annual cost math: what you actually spend over 12 months

Monthly rates look manageable. The annual number is where the commitment becomes concrete. Below is the math for each provider at its most economical plan:

• Alloy Health: $169/mo × 12 = ~$2,028/yr.
• Mochi Health: $178/mo × 12 = ~$2,136/yr.
• Fridays (annual plan): $150/mo × 12 = ~$1,800/yr — the lowest annual cost we found.
• Henry Meds (12-month prepay): $197/mo × 12 = ~$2,364/yr.
• Hers (entry level): $298/mo × 12 = ~$3,576/yr — brand Wegovy at the starting dose.
• Ro (annual membership + starting dose): $223/mo × 12 = ~$2,676/yr.
• Brand Wegovy via NovoCare (ongoing self-pay): $349/mo × 12 = ~$4,188/yr; $249/mo with 12-month subscription = ~$2,988/yr.
• Wegovy with commercial insurance + NovoCare savings card: $25/mo × 12 = $300/yr — if you qualify.

The insurance path, if available to you, beats every compounded program by a wide margin. The NovoCare 12-month subscription for Wegovy ($249/mo) is competitive with Mochi and Henry Meds once you factor in that it is FDA-approved brand medication. Compounded programs make the most financial sense when insurance does not cover Wegovy and you are paying cash.

How to choose — and red flags to watch for

Price is one dimension. A few others matter when you are comparing programs:

• Confirm the all-in maintenance rate before enrolling. Ask the provider: what will I pay at month three, month six, and at the dose I will likely need long-term? Get it in writing.
• Ask which pharmacy your program uses. A PCAB-accredited or otherwise verified 503A pharmacy is a meaningful quality signal. Programs that cannot name their pharmacy warrant skepticism.
• Check your state. Compounding restrictions vary. Alloy does not serve seven states. Confirm availability before giving your payment information.
• Dose escalation pricing. Henry Meds (and several others) charge more per month at higher doses. Request the full dose-cost ladder.
• Labs. Some programs include baseline labs; others charge separately ($75–$150 is typical). Ask directly.
• Introductory rates vs. maintenance rates. A $99 first month that jumps to $297 at month two is not a $99 program.
• Watch for 'same active ingredient as Ozempic/Wegovy' marketing. The FDA flagged this exact language in warning letters to Hers and Hims in September 2025. It is a sign a provider may be overstating the regulatory equivalence of their compounded product.
• Insurance check. Before paying cash for anything, run your prescription through your insurance portal. Wegovy coverage has expanded significantly, and the NovoCare savings card can drop your copay to $25/mo with qualifying commercial insurance.

Why semaglutide matters specifically for women in perimenopause

The weight changes that hit in your forties are not simply a matter of calorie balance. Declining estrogen worsens insulin sensitivity, shifts fat distribution toward the abdomen, and disrupts the GLP-1 and leptin pathways that signal fullness. Semaglutide works partly by mimicking GLP-1 — the same peptide that perimenopause blunts. That alignment is why obesity-medicine physicians increasingly reach for GLP-1 medications specifically during the menopause transition.

Several programs — Alloy in particular — combine semaglutide prescribing with hormone therapy, recognizing that the two interventions address different aspects of the same problem. If you have not already discussed HRT alongside any GLP-1 consideration, it is a conversation worth having with your prescriber.